Equities research analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post earnings of ($0.50) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from ($0.53) to ($0.44). Syros Pharmaceuticals reported earnings per share of ($0.58) in the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The firm is scheduled to issue its next earnings results on Monday, March 11th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.86) per share for the current financial year, with EPS estimates ranging from ($1.92) to ($1.77). For the next year, analysts expect that the business will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, November 1st. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.02). The business had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.72 million.
A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research report on Tuesday, July 17th. BidaskClub raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 31st. HC Wainwright reaffirmed a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, August 8th. Finally, Cann reaffirmed a “buy” rating and set a $26.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, August 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $19.00.
NASDAQ:SYRS opened at $8.06 on Wednesday. Syros Pharmaceuticals has a twelve month low of $6.25 and a twelve month high of $15.88. The company has a market cap of $261.16 million, a price-to-earnings ratio of -3.78 and a beta of 0.78.
Large investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $119,000. MetLife Investment Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $134,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Syros Pharmaceuticals by 299.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after buying an additional 9,691 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $177,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $186,000. 60.74% of the stock is owned by hedge funds and other institutional investors.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Featured Article: What is a put option?
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.